[EN] COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS<br/>[FR] COMPOSÉS ET COMPOSITIONS PHARMACEUTIQUES POUR TRAITER DES TROUBLES ASSOCIÉS AUX RÉCEPTEURS 5-HT1A ET 5-HT2A
申请人:ACHE LAB FARMACEUTICOS SA
公开号:WO2012037634A1
公开(公告)日:2012-03-29
This invention is related to the alkyl-piperazine-phenyl 4 (3H)-quinazolinones general formula (I) compounds, pharmacologicaly active and able to act on the 5-HT1A and 5-HT2A serotonin receptors in a manner that promotes the control, relief or cure of disorders associated with these receptors, and pharmaceutical compositions containing the compounds for the treatment of disorders associated with these receptors. These compounds and their pharmaceutical compositions are useful in the treatment of conditions such as depression, anxiety, phobias, addictions, aggressiveness, impulsiveness, panic, psychotic, eating and sleep disorders, obsessive-compulsive disorder and female sexual dysfunctions, among other disorders associated with these receptors.
这项发明涉及与烷基-哌嗪基苯基4(3H)-喹唑啉酮通式(I)化合物相关,这些化合物在药理学上活跃,并能通过促进对5-HT1A和5-HT2A 5-羟色胺受体的作用来控制、缓解或治疗与这些受体相关的疾病,并且含有这些化合物的药物组合物用于治疗与这些受体相关的疾病。这些化合物及其药物组合物在治疗抑郁症、焦虑症、恐惧症、成瘾、攻击性、冲动性、恐慌、精神病、进食和睡眠障碍、强迫症和女性性功能障碍等疾病方面具有用处,这些疾病与这些受体有关。